RxDoctor Payments DataLook up a doctor →

Firas Hijazi, MD

Anesthesiology · Laplace, LANPI 1962415943

Payments from drug & device makers

$9,353in general payments, 2019–2025

Across 351 payments — averaging $26.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Abbott$2K
  • Collegium Pharmaceutical, Inc.$808
  • Amgen$588
  • Boston Scientific$527
  • Pfizer$411
  • plus $3K from 37 others

What the payments were for

  • Travel & lodging$1,73919%
  • Food & beverage$7,61481%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,353 in reported general payments places this provider in the 95th percentile of 497 anesthesiology providers in Louisiana.

See all anesthesiology providers in Louisiana

Medicare billing

Part B allowed, 2024
$174,337
Medicare patients
205
Services billed
2,322

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen5,917$210,581
RelistorMethylnaltrexone Bromide84$203,040
MovantikNaloxegol Oxalate286$132,692
Nurtec OdtRimegepant Sulfate63$86,518
ZtlidoLidocaine98$78,638
BelbucaBuprenorphine Hcl106$78,203
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen3,576$75,445
LinzessLinaclotide126$68,936
Xtampza ErOxycodone Myristate119$66,495
Lidocaine498$65,308
Ajovy AutoinjectorFremanezumab-Vfrm22$23,969
Gabapentin2,317$23,702
Oxycodone Hcl976$20,368
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl109$19,890
Fentanyl236$19,219

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$257$203,04084 claims
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er, Nucynta$808$159,450236 claims
Redhill Biopharma Inc.Movantik$242$132,692286 claims
AbbVieLinzess, Botox$129$86,915154 claims
PfizerNurtec Odt$411$86,51863 claims
Scilex Pharmaceuticals Inc.Ztlido$373$78,63898 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 497 anesthesiology providers in Louisiana.

Other anesthesiology in Laplace

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →